Avoid common mistakes on your manuscript.
Objective
To address a significant gap in research and clinical practice by developing the global conceptual definition of Sarcopenia.
Methodology
Study design
Two-phase Delphi study with participants from leading international musculoskeletal organisations and sarcopenia societies [1]. A steering committee was formed of representatives from each continent/region (Asia, Europe, North America, South America, New Zealand/Australia). The steering committee then developed a glossary of research terms on sarcopenia [2]. Following this, a list of statements on critical aspects of sarcopenia was developed and finalised.
Participants
Invitations to complete an online survey were sent to international experts from academic, industry, and healthcare professions. All participants including steering committee members completed a declaration of interest form prior to participation.
Statistical analysis
Prespecified criteria were set by the steering committee including a two-phase study design and an acceptable threshold of > 80% for accepted statements [1].
Findings
Participants
107 participants (64% men) from 29 countries and across 7 continents/regions completed the Delphi. The majority were residing in Europe (40%), Asia (22%) and North America (19%). Participants reported their primary role as academic professionals (76 [71%]), health professional (23 [22%), industry professionals (3 [2%]), or other-mixed (5 [5%]).
Accepted and rejected statements
Across the three facets of sarcopenia; ‘general aspects’, ‘components’ and outcomes’, 20 statements were accepted with strong agreement and 4 rejected with low agreement.
Figure 1 shows the list of accepted and rejected statements
Key points
General aspects
Sarcopenia is a disease of skeletal muscle; the definition will be the same for research and clinical practice; the definition will not depend on age, setting of care or clinical condition.
Components
The definition will comprise of both reduced muscle mass and strength, as well as muscle-specific strength. Physical performance will not be considered as a component of sarcopenia but instead as an outcome.
Outcomes
Sarcopenia increases a host of adverse health outcomes (e.g. fragility fractures, disability, poor quality of life), nursing home admissions and premature mortality. Impaired physical performance will be considered a measurable outcome of sarcopenia.
Figure 2 shows the global conceptual definition of sarcopenia that will be used to develop an operationalized definition
Summary
The global conceptual definition of sarcopenia has been developed using an International Delphi Study including academic, industry and healthcare professionals from leading musculoskeletal organisations and sarcopenia societies. This inclusive approach will serve as a strong backbone to develop an operational definition of sarcopenia for research and clinical settings.
Future directions
Three working groups are currently underway to develop an operational definition of sarcopenia. These working groups, comprising of experts on specific sarcopenia topics including components and outcomes of the disease, are expected to finalise the operational definition in the coming year(s).
The Global Leadership Initiative in Sarcopenia (GLIS) represents a significant advancement in the field to improve the prevention, diagnosis and treatment of this muscle disease.
Data Availability
No datasets were generated or analysed during the current study.
References
Kirk B, Cawthon PM, Arai H et al (2024) The conceptual definition of sarcopenia: Delphi consensus from the global leadership initiative in sarcopenia (GLIS). Age Ageing. https://doi.org/10.1093/ageing/afae052
Cawthon PM, Visser M, Arai H et al (2022) Defining terms commonly used in sarcopenia research: a glossary proposed by the global leadership in sarcopenia (GLIS) steering committee. Eur Geriatr Med 13:1239–1244. https://doi.org/10.1007/S41999-022-00706-5
Acknowledgements
The list of societies and organisations taking part in the GLIS initiative
Aging in Motion (AIM) coalition/Alliance for Aging Research (AAR). American Geriatrics Society (AGS). American Society for Bone and Mineral Research (ASBMR). Asian Association for Frailty and Sarcopenia (AAFS). Australian and New Zealand Society for Sarcopenia and Frailty Research (ANZSSFR). European Association for the Study of Obesity (EASO). European Geriatric Medicine Society (EuGMS). European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). European Society for Clinical Nutrition and Metabolism (ESPEN)/ Global Leadership Initiative on Malnutrition (GLIM). Gerontological Society of America (GSA). International Association of Gerontology and Geriatrics (IAGG). International Conference on Frailty and Sarcopenia Research (ICFSR). International Osteoporosis Foundation (IOF). Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD).
Author information
Authors and Affiliations
Consortia
Contributions
All authors contributed to the original manuscript
Corresponding author
Ethics declarations
Conflict of interest
All authors declarations of conflicts of interests and declarations of sources of funding can be read here: https://www.eugms.org/fileadmin/images/news/2022/GLIS_Steering_Committee_Rev3.pdf
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The list of societies and organisations taking part in the GLIS initiative are mentioned in Acknowledgements.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Kirk, B., Cawthon, P.M., Arai, H. et al. An executive summary on the Global conceptual definition of Sarcopenia. Aging Clin Exp Res 36, 153 (2024). https://doi.org/10.1007/s40520-024-02798-4
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s40520-024-02798-4